Preferences help
enabled [disable] Abstract
Number of results
2002 | 49 | 3 | 583-596
Article title

Recognition and repair of DNA-cisplatin adducts.

Title variants
Languages of publication
Anticancer activity of cisplatin (cis-diamminedichloroplatinum) is believed to result from its interaction with DNA. The drug reacts with nucleophilic sites in DNA forming monoadducts as well as intra- and interstrand crosslinks. DNA-cisplatin adducts are specifically recognized by several proteins. They can be divided into two classes. One constitutes proteins which recognize DNA damage as an initial step of the nucleotide excision and mismatch repair pathways. The other class contains proteins stabilizing cellular DNA-protein and protein-protein complexes, including non-histone proteins from the HMG (high-mobility-group) family. They specifically recognize 1,2-interstrand d(GpG) and d(ApG) crosslinks of DNA-cisplatin adducts and inhibit their repair. Many HMG-domain proteins can function as transcription factors, e.g. UBF, an RNA polymerase I transcription factor, the mammalian testis-determining factor SRY and the human mitochondrial transcription factor mtTFA. Moreover, it seems that some proteins, which probably recognize DNA-cisplatin adducts non-specifically, e.g. actin and other nuclear matrix proteins, can disturb the structural and functional organization of the nucleus and whole cell. The formation of complexes between DNA and proteins in the presence of cisplatin and the changes in the cell architecture may account for the drug cytotoxicity.
Physical description
  • Department of Molecular Genetics, University of Łódź, S. Banacha 12/16, 90-237 Łódź, Poland
  • Department of Molecular Genetics, University of Łódź, S. Banacha 12/16, 90-237 Łódź, Poland
  • Aboussekhra A, Wood RD. (1994) Repair of ultraviolet light-damaged DNA by mammalian cells and Saccharom y ces cerevisiae. Curr Opin Genet Dev.; 4: 212-20.
  • Aebi S, Kurdihaidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res.; 56: 3087-90.
  • Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R. (1996) Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res.; 56: 1374-81.
  • Arioka H, Nishio K, Ishida T, Fukumoto H, Fukuoka K, Nomoto T, Kurokawa H, Yokote H, Abe S, Saijo N. (1999) Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells. Jpn J Cancer Res.; 90: 108-15.
  • Asai A, Kiyozuka Y, Yoshida R, Fujii T, Hioki K, Tsubura A. (1998) Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res.; 18: 1465-72.
  • Bellon SF, Coleman JH, Lippard SJ. (1991) DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry.; 30: 8026-35.
  • Blasiak J, Kowalik J. (2001) Protective action of vitamin C against DNA damage induced by selenium-cisplatin conjugate. Acta Biochim Polon.; 48: 233-40.
  • Blasiak J, Kadlubek M, Kowalik J, Romanowicz-Makowska H, Pertynski T. (2002) Inhibition of telomerase activity in endometrial cancer cells by selenium-cisplatin conjugate despite suppression of its DNA-damaging activity by sodium ascorbate. Teratog Carcinog Mutagen.; 22: 73-82.
  • Blasiak J, Kowalik J, Malecka-Panas E, Drzewoski J, Wojewodzka M. (2000) DNA damage and repair in human lymphocytes exposed to three anticancer platinum drug. Teratog Carcinog Mutagen.; 20: 119-31.
  • Blasiak J, Kowalik J, Trzeciak A, Wojewodzka M. (1999) Cytotoxicity and DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs. Neoplasma.; 46: 61-3.
  • Brown SJ, Chow CS, Lippard SJ. (1994) Platinum-based anticancer drugs. In Encyclopaedia of inorganic chemistry. King RB. ed, vol 6, pp 3305-15. John Wiley, Sons, Chichester.
  • Brown SJ, Kellett PJ, Lippard SJ. (1993) Ixr1, ayeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science.; 261: 603-5.
  • Burger AM, Double JA, Newell DR. (1997) Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer.; 33: 638-44.
  • Bustin M, Reeves R. (1996) High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol.; 54: 35-100.
  • Chaney SG, Sancar A. (1996) DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst.; 88: 1346-60.
  • Chao CC-K, Huang S-L, Lee Y-L, Lin-Chao S. (1991) Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum(II). Biochem J.; 277: 875-8.
  • Chao JC, Wan XS, Engelsberg BN, Rothblum LI, Billings PC. (1996) Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin. Biochim Biophys Acta.; 1307: 213-9.
  • Chen G, Hutter KJ, Zeller WJ. (1995) Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol.; 11: 273-81.
  • Chow SC, Barnes CM, Lippard SJ. (1995) A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.Biochemistry.; 34: 2956-64.
  • Chu G. (1994) Cellular responses to cisplatin. J Biol Chem.; 269: 787-90.
  • Cleaver JE, Charles WC, McDowell ML, Sadinski WJ, Mitchell DL. (1995) Overexpression of the XPA repair gene increases resistance to ultraviolet radiation in human cells by selective repair of DNA damage. Cancer Res.; 55: 6152-60.
  • Clubb BH, Locke M. (1998) Peripheral nuclear matrix actin forms perinuclear shells. J Cell Biochem.; 70: 240-51.
  • Cohen SM, Lippard SJ. (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol.; 67: 93-130.
  • Comess KM, Burstyn JN, Essigmann JM, Lippard SJ. (1992) Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry.; 31: 3975-90.
  • Corda Y, Job C, Anin MF, Leng M, Job D. (1991) Transcription by eucaryotic and procaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry.; 30: 222-30.
  • Coste F, Malinge J-M, Serre L, Shepard W, Roth M, Leng M, Zelwer C. (1999) Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 Å resolution: hydration at the platinated site. Nucleic Acids Res.; 27: 1837-46.
  • Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. (1994) Messenger RNA levels of XPA and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest.; 94: 703-8.
  • de Lange T. (1992) Human telomeres are attached to the nuclear matrix. EMBO J.; 11: 717-24.
  • Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. (2000) Cisplatin resistance and oncogenes - a review. Anticancer Drugs.; 11: 225-36.
  • Dijt FJ, Fichtinger-Schepman AM, Berends F, Reedijk J. (1988) Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblast. Cancer Res.; 48: 6058-62.
  • Duckett DR, Drummond JT, Murchie AIH, Reardon JT, Sancar A, Lilley DM, Modrich P. (1996) Human MutSa recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A.; 93: 6443-7.
  • Farid RS, Bianchi ME, Falciola L, Engelsberg BN, Billings PC. (1996) Differential binding of HMG1, HMG2 and a single HMG domain to cisplatin-damaged DNA. Toxicol Appl Pharm a col.; 141: 532-9.
  • Ferraro A, Grandi P, Eufemi M, Altieri F, Turano C. (1992) Crosslinking of nuclear proteins to DNA by cis-diamminedichloroplatinum in intact cells. FEBS Lett.; 307: 383-5.
  • Fichtinger-Schepman AMJ, van der Veer JL, den Hertog JHJ, Lohman PHM, Reedijk J. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry.; 24: 707-13.
  • Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB. (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res.; 56: 4881-6.
  • Fraval HNA, Rawlings CJ, Roberts JJ. (1978) Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products, which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. Mutat Res.; 51: 121-32.
  • Grosschedl R, Giese K, Pagel J. (1994) HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet.; 10: 94-100.
  • Guo Z, Sadler PJ. (1999) Metals in medicine. Angew Chem Int Ed.; 38: 1512-31.
  • Hayes J, Scovell WM. (1991) Cis-diamminedichloroplatinum(II) modified chromatin and nucleosomal core particle. Biochim Biophys Acta.; 1089: 377-85.
  • Heminger K, Hartson SD, Rogers J, Matts RL. (1997) Cisplatin inhibits protein synthesis in rabbit reticulocyte lysate by causing an arrest in elongation. Arch Biochem Biophys.; 344: 200-7.
  • Hoffmann J-S, Pillaire M-J, Garcia-Estefania D, Lapalu S, Villani G. (1996) In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase and human immunodeficiency virus type I reverse transcriptase is highly mutagenic. J Biol Chem.; 271: 15386-92.
  • Huang J-C, Zamble DB, Reardon JT, Lippard SJ, Sancar A. (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA.; 91: 10394-8.
  • Hughes EN, Engelsberg BN, Billings PC. (1992) Purification of nuclear proteins that bind to cisplatin-damaged DNA. J Biol Chem.; 267: 13520-7.
  • Ishibashi T, Lippard SJ. (1998) Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci U S A.; 95: 4219-23.
  • Jantzen H, Admon A, Bell SP, Tijan R. (1990) Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins.Nature.; 344: 830-6.
  • Jordan P, Carmo-Fonseca M. (1998) Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res.; 26: 2831-6.
  • Jordan P, Carmo-Fonseca M. (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci.; 57: 1229-35.
  • Kartalou M, Essigmann JM. (2001) Recognition of cisplatin adducts by cellular proteins. Mutat Res.; 478: 1-21.
  • Kartalou M, Samson LD, Essigmann JM. (2000) Cisplatin adducts inhibit 1,N6-ethenoadenine repair by interacting with the human 3-methyladenine DNA glycosylase. Biochemistry.; 39: 8032-8.
  • Larminat F, Bohr VA. (1994) Role of the human ERCC1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res.; 22: 3005-10.
  • Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E. (2000) Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res.; 20: 645-52.
  • Lin X, Kim HK, Howell SB. (1999) The role of DNA mismatch repair in cisplatin mutageneticity. J Inorg Biochem.; 77: 89-93.
  • Locker D, Decoville M, Maurizot JC, Bianchi ME, Leng M. (1995) Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism. J Mol Biol.; 246: 243-7.
  • Loehrer PJ, Einhorn LH. (1984) Diagnosis and treatment: cisplatin. Ann Intern Med.; 100: 704-13.
  • Malinge J-M, Giraud-Panis M-J, Leng M. (1999) Interstrand cross-links of cisplatin induce striking distortions in DNA. J Inorg Biochem.; 77: 23-9.
  • Malinge J-M, Perez C, Leng M. (1994) Base sequence-independent distorsions induced by interstrand cross-links in cis-diamminedichloroplatinum (II)-modified DNA. Nucleic Acids Res.; 22: 3834-9.
  • McA'Nulty MM, Whitehead JP, Lippard SJ. (1996) Binding of Ixr1, a yeast HMG-domian protein, to cisplatin-DNA adducts in vitro and in vivo. Biochemistry.; 35: 6089-99.
  • Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Leichman L. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol.; 16: 309-16.
  • Miao F, Bouziane M, Dammann R, Masutani Ch, Hanaoka F, Pfeifer G, O'Connor TR. (2000) 3-Methyladenine-DNA glycosylase (MPG protein) interacts with human RAD23 proteins. J Biol Chem.; 275: 28433-8.
  • Miller CA, Cohen MD, Costa M. (1991) Complexing of actin and other nuclear proteins to DNA by cis-diamminedichloroplatinum(II) and chromium compounds. Carcinogenesis.; 12: 269-76.
  • Modrich P. (1997) Strand-specific mismatch repair in mammalian cells. J Biol Chem.; 272: 24727-30.
  • Moggs JG, Szymkowski DE, Yamada M, Karran P, Wood RD. (1997) Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucleic Acids Res.; 25: 480-90.
  • Nakayasu H, Ueda K. (1985) Association of rapidly-labelled RNAs with actin in nuclear matrix from mouse L5178Y cells. Exp Cell Res.; 160: 319-30.
  • Nardozza TA, Quigley MM, Getzenberg RH. (1996) Association of transcription factors with the nuclear matrix. J Cell Biochem.; 61: 467-77.
  • Nguyen E, Besombes D, Debey P. (1998) Immunofluorescent localization of actin in relation to transcription sites in mouse pronuclei. Mol Reprod Dev.; 50: 263-72.
  • Niedner H, Christen R, Lin X, Kondo A, Howell SB. (2001) Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol.; 60: 1153-60.
  • Nishio M, Arioka H, Nishio K, Kubota N, Heike Y, Ohata M, Saijo N. (1994) Overexpression of cisplatin-inducible proteins that are recognized by anti-HMG antibody in cisplatin-resistant human lung cancer cell lines. Cell Pharmacol.; 1: 251-5.
  • Ohndorf U-M, Whitehead JP, Raju NL, Lippard SJ. (1997) Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. Biochemistry.; 36: 14807-15.
  • Ohndorf U-M, Rould MA, He Q, Pabo CO, Lippard SJ. (1999) Basis for recognition of cisplatin-modified DNA by high-mobility- group proteins. Nature.; 399: 708-12.
  • Olinski R, Wedrychowski A, Schmidt WN, Briggs RC, Hnilica LS. (1987) In vivo DNA-protein cross-linking by cis- and trans-diamminedichloroplatinum(II). Cancer Res.; 47: 201-5.
  • Parker RJ, Eastman A, Bostick-Bruton F, Reed E. (1991) Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced DNA repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest.; 87: 772-7.
  • Pil PM, Lippard SJ. (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science.; 256: 234-7.
  • Pontiggia A, Rimini R, Harley VR, Goodfellow PN, Lovell-Badge R, Bianchi ME. (1994) Sex-reversing mutations affect the architecture of SRY-DNA complexes. EMBO J.; 13: 6115-24.
  • Roberge M, Gasser SM. (1992) DNA loops: structural and functional properties of scaffold-attached regions. Mol Microbiol.; 6: 419-23.
  • Rosenberg B, Van Camp L, Grimley EB, Thomson AJ. (1967) The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem.; 242: 1347-52.
  • Rosenberg B, Van Camp L, Krigas T. (1965) Inhibition of cell division by electrolysis products from a platinum electrode. Nature.; 205: 698-9.
  • Sahlas DJ, Milankov K, Park PC, De Boni U. (1993) Distribution of snRNPs, splicing factor SC-35 and actin in interphase nuclei: immunocytochemical evidence for differential distribution during changes in functional states. J Cell Sci.; 105: 347-57.
  • Sato P, Rosenberg J. (1993) Cisplatin inhibition of translation. Curr Topics Mol Pharmacol.; 1: 75-96.
  • Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, Skorski T. (2002) Fusion tyrosine kinases induce resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis. Mol Cell Biol.; 22: 4189-201.
  • Suo Z, Lippard SJ, Johnson KA. (1999) Single d(GpG) cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry.; 38: 715-26.
  • Szymkowski DE, Yarema K, Essigmann JM, Lippard SJ, Wood RD. (1992) An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci U S A.; 89: 10772-6.
  • Takahara PM, Frederick CA, Lippard SJ. (1996) Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J Am Chem Soc.; 118: 12309-21.
  • Treiber DK, Zhai XQ, Jantzen HM, Essigmann JM. (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transciption factor hUBF (human upstream binding factor). Proc Natl Acad Sci U S A.; 91: 5672-6.
  • Trimmer EE, Essigmann JM. (1999) Cisplatin. Essays Biochem.; 34: 191-211.
  • Trimmer EE, Zamble DB, Lippard SJ, Essigmann JM. (1998) Human testis-determining factor SRY binds to the major DNA adducts of cisplatin and a putative target sequence with comparable affinities. Biochemistry.; 37: 352-62.
  • Turchi JJ, Henkels KM, Hermanson IL, Patrick SM. (1999) Interactions of mammalian proteins with cisplatin-damaged DNA. J Inorg Biochem.; 77: 83-7.
  • Turchi JJ, Li M, Henkels KM. (1996) Cisplatin-DNA binding specificity of calf high-mobility group 1 protein. Biochemistry.; 35: 2992-3000.
  • Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG. (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res.; 58: 3579-85.
  • van Holde KE. (1988) Chromatin. Springer- Verlag, New York.
  • van Wijnen AJ, Bidwell JP, Fey EG, Penman S, Lian JB, Stein JL, Stein GS. (1993) Nuclear matrix association of multiple sequence-specific DNA binding activities related to SP-1, ATF, CCAAT, E/EBP, OCT-1 and AP-1. Biochemistry.; 32: 8397-402.
  • Varga-Weisz P, van Holde KE, Zlatanova J. (1994) Competition between linker histones and HMG1 for binding to four-way junction DNA: implications for transcription. Biochem Biophys Res Commun.; 203: 1904-11.
  • Vichi P, Coin F, Renaud J-P, Vermeulen W, Hoeijmakers JHJ, Moras D, Egly J-M. (1997) Cisplatin- and UV-damaged DNA lure the basal transcription factor TFII/TBP. EMBO J.; 16: 7444-56.
  • Wood RD. (1996) DNA repair in Eukaryotes. Annu Rev Biochem.; 65: 135-67.
  • Wozniak K, Walter Z. (2002) Immunospecific protein of 34.5 kDa from DNA-protein cross-links induced by cis- and trans-diamminedichloroplatinum. Cell Biol Int.; 26: 495-503.
  • Yamada M, O'Regan E, Brown R, Karran P. (1997) Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res.; 25: 491-5.
  • Yaneva J, Leuba SH, van Holde K, Zlatanova J. (1997) The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA. Proc Natl Acad Sci USA.; 94: 13448-51.
  • Yu JJ, Dabholkar M, Bennett WP, Welsh JA, Mu C, Bostick-Bruton F, Reed E. (1996) Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. Int J Oncol.; 8: 313-7.
  • Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry.; 35: 10004-13.
  • Zeng H, Wang K, Wang B, Zhang Y. (1996) Studies on the thermokinetic characterisation of actin polymerization and the effect of cisplatin. Int J Biol Macromol.; 18: 161-6.
  • Zlatanova J, Yaneva J, Leuba SH. (1998) Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J.; 12: 791-9.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.